WO2010095840A2 - Donepezil resin complex - Google Patents

Donepezil resin complex Download PDF

Info

Publication number
WO2010095840A2
WO2010095840A2 PCT/KR2010/000947 KR2010000947W WO2010095840A2 WO 2010095840 A2 WO2010095840 A2 WO 2010095840A2 KR 2010000947 W KR2010000947 W KR 2010000947W WO 2010095840 A2 WO2010095840 A2 WO 2010095840A2
Authority
WO
WIPO (PCT)
Prior art keywords
donepezil
tablet
resin complex
present
complex
Prior art date
Application number
PCT/KR2010/000947
Other languages
French (fr)
Korean (ko)
Other versions
WO2010095840A3 (en
Inventor
유무희
차봉진
김정훈
전준호
강경훈
Original Assignee
동아제약주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 동아제약주식회사 filed Critical 동아제약주식회사
Publication of WO2010095840A2 publication Critical patent/WO2010095840A2/en
Publication of WO2010095840A3 publication Critical patent/WO2010095840A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction

Abstract

The present invention relates to a donepezil resin complex consisting of donepezil or pharmaceutically acceptable salts thereof and a cation-exchange resin, and to oral preparations containing same. The complex of the present invention is advantageous in that it can effectively mask the unpleasant taste of donepezil or of the salts thereof, and therefore can be formulated into a variety of dosage forms such as a tablet, an orally disintegrating tablet, a troche tablet, a suspension, etc.
PCT/KR2010/000947 2009-02-17 2010-02-16 Donepezil resin complex WO2010095840A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020090012733A KR101124796B1 (en) 2009-02-17 2009-02-17 Complex of donepezil-resin
KR10-2009-0012733 2009-02-17

Publications (2)

Publication Number Publication Date
WO2010095840A2 true WO2010095840A2 (en) 2010-08-26
WO2010095840A3 WO2010095840A3 (en) 2011-01-20

Family

ID=42634311

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2010/000947 WO2010095840A2 (en) 2009-02-17 2010-02-16 Donepezil resin complex

Country Status (2)

Country Link
KR (1) KR101124796B1 (en)
WO (1) WO2010095840A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200064951A (en) 2018-11-29 2020-06-08 동국제약 주식회사 Oral dissolving film formulation containing an active ingredient and the preparation method for the same
KR102194794B1 (en) * 2019-01-22 2020-12-23 충북대학교 산학협력단 Method for producing donepezil sustained release microparticle with enhanced adaptability of taking medicine and initial burst inhibition

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4221778A (en) * 1979-01-08 1980-09-09 Pennwalt Corporation Prolonged release pharmaceutical preparations
US20050181050A1 (en) * 2004-01-28 2005-08-18 Collegium Pharmaceutical, Inc. Dosage forms using drug-loaded ion exchange resins
US20080118570A1 (en) * 2006-11-20 2008-05-22 Zhi Liu Polymer coated drug-ion exchange resins and methods
US20080279846A1 (en) * 2007-05-11 2008-11-13 Thomas Jefferson University Methods of treatment and prevention of neurodegenerative diseases and disorders

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4221778A (en) * 1979-01-08 1980-09-09 Pennwalt Corporation Prolonged release pharmaceutical preparations
US20050181050A1 (en) * 2004-01-28 2005-08-18 Collegium Pharmaceutical, Inc. Dosage forms using drug-loaded ion exchange resins
US20080118570A1 (en) * 2006-11-20 2008-05-22 Zhi Liu Polymer coated drug-ion exchange resins and methods
US20080279846A1 (en) * 2007-05-11 2008-11-13 Thomas Jefferson University Methods of treatment and prevention of neurodegenerative diseases and disorders

Also Published As

Publication number Publication date
KR20100093685A (en) 2010-08-26
KR101124796B1 (en) 2012-03-23
WO2010095840A3 (en) 2011-01-20

Similar Documents

Publication Publication Date Title
WO2009114118A3 (en) Oral pharmaceutical compositions of buprenorphine and method of use
WO2013183062A3 (en) Palatable formulations of ibuprofen
WO2007058602A3 (en) Novel 2-amino-imidazole-4-one compounds and their use in the manufacture of a medicament to be used in the treatment of cognitive impairment, alzheimer’s disease, neurodegeneration and dementia.
EP2947073A3 (en) Fused ring analogues of anti-fibrotic agents
WO2010088000A3 (en) Antifibrotic compounds and uses thereof
IL184148A (en) Substituted triazole derivatives as oxytocin antagonists, pharmaceutical compositions comprising them and their use in the preparation of medicaments for treating disorders where inhibition of oxytocin produces a beneficial effect
WO2011012322A3 (en) Synthesis and use of vildagliptin for the preparation of pharmaceutical dosage forms
WO2008128115A3 (en) Low-dose doxepin formulations
WO2011104652A3 (en) Veterinary compositions
WO2010116385A3 (en) Pharmaceutical compositions for alleviating unpleasant taste
TW200724532A (en) Pyrimidinecarboxylic acid derivatives and their use
MX2012001691A (en) Orally disintegrating compositions of linaclotide.
MX2015001917A (en) Pharmaceutical compositions of memantine.
DOP2011000406A (en) COMPOSITIONS OF SOLID PHARMACEUTICAL FIXED DOSES THAT INCLUDE IRBESARTAN AND AMLODIPIN, ITS PREPARATION AND THEIR APPLICATION IN THERAPEUTICS
NZ589293A (en) Antiallergic marine biopolymers comprising iota-carrageenan
WO2012087255A3 (en) Pharmaceutical formulations comprising imatinib
WO2010012459A3 (en) A process for the preparation of solifenacin salts and their inclusion into pharmaceutical dosage forms
WO2007083190A3 (en) Water insoluble helichrysum extract, process for preparing the same and uses thereof
WO2010106433A3 (en) Herbal cleansing composition and method of preparing the same
WO2014144407A8 (en) Dual use oral pharmaceutical composition tablets of sulfate salts and methods of use thereof
LV14345A (en) 4-[ethyl(dimethyl)ammonio]butanoate and their use in the treatment of cardiovascular diseases
WO2011055931A3 (en) Composition for preventing or treating diseases caused by influenza viruses
WO2010095840A2 (en) Donepezil resin complex
WO2010119450A3 (en) An improved process for the preparation of desmopressin or its pharmaceutically acceptable salts
WO2008116737A3 (en) Capsule containing plant preparations

Legal Events

Date Code Title Description
DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10743915

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10743915

Country of ref document: EP

Kind code of ref document: A2